UK markets close in 8 hours 4 minutes
  • FTSE 100

    7,243.16
    +74.51 (+1.04%)
     
  • FTSE 250

    18,738.93
    +101.95 (+0.55%)
     
  • AIM

    879.10
    +3.89 (+0.44%)
     
  • GBP/EUR

    1.1617
    +0.0024 (+0.20%)
     
  • GBP/USD

    1.2122
    +0.0019 (+0.16%)
     
  • BTC-GBP

    15,761.65
    -77.07 (-0.49%)
     
  • CMC Crypto 200

    412.25
    -7.89 (-1.88%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • DOW

    31,097.26
    +321.86 (+1.05%)
     
  • CRUDE OIL

    108.61
    +0.18 (+0.17%)
     
  • GOLD FUTURES

    1,812.20
    +10.70 (+0.59%)
     
  • NIKKEI 225

    26,153.81
    +218.19 (+0.84%)
     
  • HANG SENG

    21,821.72
    -38.07 (-0.17%)
     
  • DAX

    12,904.77
    +91.74 (+0.72%)
     
  • CAC 40

    5,987.25
    +56.19 (+0.95%)
     

Bioabsorbable Stents Global Market Report 2022

·3-min read
ReportLinker
ReportLinker

Major players in the bioabsorbable stents market are Abbott Laboratories, Reva Medical, Elixir Medical Corporation, Biotronik SE & Co. KG, Amaranth Medical Inc. , Zorion Medical, Tepha, Inc. , S3V Vascular Technologies, ICON Interventional Systems, and Arterius Limited.

New York, May 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bioabsorbable Stents Global Market Report 2022" - https://www.reportlinker.com/p06280861/?utm_source=GNW


The global bioabsorbable stents market is expected to grow from $0.29 billion in 2021 to $0.31 billion in 2022 at a compound annual growth rate (CAGR) of 8.1%. The market is expected to grow to $0.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%.

The bioabsorbable stents market consists of sales of bioabsorbable stents and related services.Bioabsorbable stents, also known as Bioresorbable stents (BRS) or vascular scaffolds are coronary stents that can fully dissolve in the body.

These biodegradable stents are used in percutaneous coronary intervention (PCI) procedures for providing structural support to the treated vessels and preventing acute recoil & restenosis. Bioabsorbable stents are commonly used in the treatment of heart diseases.

The main products of bioabsorbable stents are polymer-based bioabsorbable stents and metal-based bioabsorbable stents.Bioresorbable stents (BRS) or vascular scaffolds are coronary stents that can fully dissolve in the body.

It is also segmented by absorption rate into slow-absorption stents and fast-absorption that are used in various applications such as coronary artery diseases, and peripheral artery diseases.

Increasing cardiovascular diseases is a key factor driving the growth of the bioabsorbable stents market.Cardiovascular disorders are the leading cause of death across the world and 4 out of 5 cardiovascular deaths are caused by strokes and heart attacks.

Moreover, one-third of such deaths occur prematurely in people under the age of 70.Bioresorbable stents are built primarily to reduce these risks of late complications, such as scaffold thrombosis or restenosis, that can happen when a conventional metal stent’s rigid metal backbone remains permanently rooted in the diseased vessel.

According to the American Heart Association, it is estimated that more than 23.6 million die due to cardiovascular diseases by 2030. Therefore, increasing cardiovascular diseases are expected to drive the growth of the bioabsorbable stents market.

The risks associated with bioabsorbable stents restrain the growth of the market.The high risks with stents force companies to withdraw their devices from the market reducing the revenues from bioabsorbable stents.

For instance, Abbott had to withdraw its product Absorb and Boston Scientific terminated their Renuvia scaffold development program as the devices showed a high risk of myocardial infarction and thrombosis. This was due to the non-uniform structure of the polymer used in the stents that makes the device susceptible to large deformation and causes flow disruption.

The drug-eluting stent (DES) is gaining significant popularity in the bioabsorbable stents market.The drug-eluting stent (DES) device was designed to avoid the regeneration of tissue that would otherwise obstruct the artery and this was a new step forward in the treatment of peripheral artery disease.

Boston Scientific launched its self-expanding drug-eluting stent (DES) peripheral artery disease (PAD) scheme which helped the company to expand its PAD portfolio.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bioabsorbable stents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Read the full report: https://www.reportlinker.com/p06280861/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting